Navigation Links
FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)
Date:5/29/2009

matology 2008 annual meeting and will be presented at the American Society of Clinical Oncology 2009 annual meeting.

About CLL

CLL is the most common adult leukemia and one of the most common malignant lymphoid diseases. In the United States, about 90,000 people are living with CLL, with approximately 15,000 estimated new cases being diagnosed in 2009. Based on 2007 worldwide estimates, leukemia (all types) accounted for more than 330,000 new cases and more than 245,000 deaths.

CLL cells are malignant B-cells that have a low concentration of CD20 molecules on their surface. B-cells normally protect the body from invading pathogens by developing into plasma cells, which make antibodies. These antibodies directly inactivate pathogens or attach to pathogens to prepare them for destruction by other white blood cells.

About Ofatumumab

Ofatumumab is an investigational monoclonal antibody that targets a membrane-proximal (close to the cell surface), small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule on B-cells. Ofatumumab also binds to the large loop of the CD20 molecule. The CD20 molecule is a key target in CLL therapy because it is highly expressed in most B-cell malignancies.

Ofatumumab is being developed under a collaboration between Genmab and the GSK Oncology and BioPharm R&D Units.

Ofatumumab is not yet approved in any country.

About GlaxoSmithKline (GSK)

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information, visit GlaxoSmithKline at www.gsk.com.

GSK Oncology is dedicated to producing innovations in cancer that
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Advisory Panel Recommends Approval of the SEDASYS(R) System
2. Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
3. FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)
4. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
5. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
6. Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
7. New Jersey American Water Lifts Precautionary Boil Water Advisory For Middlesex, Somerset and Union Counties
8. Arpida Comments on FDAs Anti-infective Drugs Advisory Committee Outcome
9. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
10. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
11. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Nanomix Inc., (Nanomix), a ... of mobile diagnostic tests to enable earlier ... pre-hospital settings, today announced it has received ... certification was awarded by the British Standards ... certification bodies. ISO 13485:2003 ...
(Date:11/26/2014)... Pa. , Nov. 25, 2014  Unilife Corporation ... of injectable drug delivery systems, today announced that its ... to present at the Piper Jaffray 26th Annual Healthcare ... a.m. EST on Tuesday, December 2, 2014. ... Internet as a "live" listen only Webcast. To listen, ...
(Date:11/26/2014)... RATON, Fla. , Nov. 25, 2014 /PRNewswire/ ... entered into a multi-product ANDA agreement with Pii ... ) under which Breckenridge and Pii expect ... the terms of the agreement, Pii will develop, ... market and distribute the products under its own ...
Breaking Medicine Technology:Nanomix Receives ISO 13485:2003 Certification 2Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2
... Reportlinker.com announces that a new market research ... ENT Devices Market Outlook in Brazil to ... Diagnostic Devices http://www.reportlinker.com/p0259722/ENT-Devices-Market-Outlook-in-Brazil-to-2017---Hearing-Aid-Devices-and-Implants-and-Diagnostic-Devices.html ... to 2017 - Hearing Aid Devices and Implants ...
... 14, 2011 New 5-year data from the longest ... show that Neupro® (rotigotine) demonstrated continued symptomatic clinical benefit ... year period, clinically significant augmentation occurred in 5.1% of ... and 3 mg/24h) and in 13.2% of patients receiving ...
Cached Medicine Technology:Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 2Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 3Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 4Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 5Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 6Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 7Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 8Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 9Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices 10New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 2New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 3New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 4New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 5New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment 6
(Date:11/27/2014)... (PRWEB) November 27, 2014 Blood-borne pathogens ... many medical precautions and procedures in place to counter ... and disposal of things tainted with menstrual blood are ... design a simpler, more sanitary way to handle tampons ... an inventor from Sonora, Calif. , He then created ...
(Date:11/27/2014)... 27, 2014 Nearly 1,100 Risperdal ... in a consolidated litigation now underway in Pennsylvania ... Documents recently updated in the Philadelphia Court of ... state proceeding, all of which involve a drug ... psychiatric conditions. Many of the cases in this ...
(Date:11/27/2014)... HealthDay Reporter WEDNESDAY, Nov. 26, 2014 ... safe and produces an immune system response that could protect ... results reported by the U.S. National Institutes of Health. ... vaccine paves the way for field-testing it in the Ebola-stricken ... as January, said Dr. Anthony Fauci, director of the NIH,s ...
(Date:11/27/2014)... NY (PRWEB) November 27, 2014 The founders ... offering stylish, comfortable and high functioning compression socks, are proud ... newly-released socks use an innovative Gradient Pressure (TM) knitting technology ... blood. , VIM & VIGR’s commitment to adding flair and ... as just functional recently caught the eye of a writer ...
(Date:11/27/2014)... 27, 2014 Tylenol lawsuits ( http://www.tylenollawsuitcenter.com/ ... injured by the medication are continuing to move forward ... looking ahead to a status conference in December, Bernstein ... Order issued earlier this year, a conference in the ... 10:00 a.m. Items likely to be discussed at the ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3
... effects of the menstrual cycle on sportswomen has suggested that ... period. The// researcher Inger Jacobson connects the incidence of injuries ... hormone which relaxes ligaments) to rise during menstruation. ... seen that women who were not on birth control ...
... Cholesterol is a chemical that is made in the liver from ... present in the blood stream. Some cholesterol is needed to keep ... conditions such as angina, heart attack and strokes due to a ... of the arteries. , ,Why Use Cholestrak? , ,We are ...
... Health has indicated the current situation with both these viral infections ... reports of 9453 cases and 157 deaths as a whole ... ,In Delhi and NCR - one of the worst affected ... have been reported from Delhi, NCR and other states. There ...
... at blocking lawyers' access to a high-profile detainee at ... //techniques "national security secrets" whose revelation could "cause extremely ... said the prisoners at secret CIA prisons must not ... on them - even to their lawyers, the Post ...
... Researchers want doctors to be ready to handle medical problems ... it. //In the present state, what happens when a person ... get back to normal conditions for treatment in time simply ... findings from a UF study show there is little difference ...
... has been simmering in the trans-fat controversy for quite a ... ally- the hydrogenated// vegetable oils! This is perhaps the last ... Asda, Sainsbury’s and Tesco have already communicated their intention of ... Journal has urged the Government to bring in a law ...
Cached Medicine News:Health News:Researchers explore medicine in space 2Health News:Researchers explore medicine in space 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: